THE GUT MICROBIOTA FOR HEALTH SUMMITMadrid, March 7-8, 2020

The gut Microbiome field is moving rapidly and the number of publications increases

exponentially impacting basic science research as well as clinical practice in numerous

areas. On behalf of the GMFH Scientific Committee, I am happy to invite you to join us in

Madrid (Spain) for the ninth annual Gut Microbiota for Health World Summit on March 7

& 8, 2020. The summit is sponsored by the European Society for Neurogastroenterology

& Motility (ESNM) and the American Gastroenterological Association (AGA), with the

endorsement of the American Neurogastroenterology and Motility Society (ANMS).

It will be an excellent occasion to learn about the new discoveries on the role of the gut

microbiome in health and diseases and how they are or will be translated to clinical

practice for the benefit of health care professionals and patients.

The 2020 program is particularly exciting with the intervention of outstanding

international faculty. We will have plenary sessions and workshops dedicated to various

aspects including the dietary and non-dietary factors shaping the gut Microbiome, the

role of the Gut Microbiome in the modulation of the immune system, Microbiome –

drug interactions, gut-brain axis, and fecal microbiota transplantation.

This interdisciplinary scientific program targets a large audience from Microbiome

scientists to health care professionals including physicians, nurses, dietitians, and

nutritionists.

We look forward to welcoming you to the summit in Madrid!

Harry Sokol, MD PhDCo-Chair of GMFH Scientific Committee

S A T U R D A Y , M A R C H 7

08:15 - 08:30 am WELCOME AND DAY 1 KICKOFF Harry Sokol (Paris, France) Fernando Azpiroz (Barcelona, Spain) 08:30 - 09:00 am KEYNOTE LECTURE: TRANSLATING MICROBIOME SCIENCE - REPLACING ROADBLOCKS WITH ROADMAPS Colin Hill (Cork, Ireland)

PLENARY SESSION 1Dietary and non dietary factors shaping the gut microbiome

Session Moderator: Dirk Haller (Munich, Germany)

09:00 - 09:30 am HOST GENETICS Emily Davenport (State College, USA) 09:30 - 10:00 am ENVIRONMENT Eran Segal (Rehovot, Israel) 10:00 - 10:30 am GEOGRAPHY/ IMMIGRATION Ran Blekhman (Minneapolis, USA)

10:30 - 11:00 am Morning Break

PLENARY SESSION 2Microbiome as orchestrator of the immune system

Session Moderator: R. Balfour Sartor (Chapel Hill, USA)

11:00 - 11:30 am MATERNAL MICROBIOME SHAPING THE IMMUNE SYSTEM OF INFANT Kathy McCoy (Calgary, Canada) 11:30 - 12:00 pm LONG TERM CONSEQUENCES OF EARLY LIFE IMPRINTING BY THE GUT MICROBIOTA Gérard Eberl (Paris, France) 12:00 - 12:30 pm MICROBIOME MODULATION OF IMMUNE SYSTEM IN IBD Harry Sokol (Paris, France)

12:30 - 02:00 pm Networking Lunch

WORKSHOPS SESSION02:00 - 03:30 pm WORKSHOPS 1, 2A, 3A & 5A 1. FMT BEYOND C. difficile Moderator: Colleen R. Kelly (Providence, USA) FMT in IBD: Jessica Allegretti (Boston, USA) FMT in metabolic syndrome: Max Nieuwdorp (Amsterdam, The Netherlands) 2A. MICROBIOME ACROSS AGE Moderator: D. Brent Polk (Los Angeles, USA) Microbiome in early life: Moran Yassour (Jerusalem, Israel) Microbiome in elderly: Paul W. O’Toole (Cork, Ireland)

3A. NUTRITION IN GUT MICROBIOTA MODULATION Moderator: Francisco Guarner (Barcelona, Spain) Fermented foods, probiotics and prebiotics in the era of microbiome science: Kevin Whelan (London, United Kingdom)

Effectofplant-baseddietongutmicrobiota: Hana Kahleova (Washington DC, USA)

5A. MICROBIOME AND GUT-BRAIN AXIS Moderator: Emeran A. Mayer (Los Angeles, USA) Gut-brainconnection:John Cryan (Cork, Ireland) Serotonin and gut microbiota: Jonathan Lynch (Los Angeles, USA)

03:30 - 04:00 pm Afternoon Break

04:00 - 05:30 pm WORKSHOPS 2B, 3B, 4 & 5B

2B. MICROBIOME ACROSS AGE Moderator: D. Brent Polk (Los Angeles, USA) Microbiome in early life: Moran Yassour (Jerusalem, Israel) Microbiome in elderly: Paul W. O’Toole (Cork, Ireland)

3B. NUTRITION IN GUT MICROBIOTA MODULATION Moderator: Francisco Guarner (Barcelona, Spain) Fermented foods, probiotics and prebiotics in the era of microbiome science: Kevin Whelan (London, United Kingdom)

Effectofplant-baseddietongutmicrobiota: Hana Kahleova (Washington DC, USA)

4. TIME TO FOCUS ON THE SMALL INTESTINE Moderator: Purna Kashyap (Rochester, USA) Dietary antigen: Alberto Caminero (Hamilton, Canada) Bileacidandsmallintestinemicrobiota:Gary D. Wu (Philadelphia, USA)

5B. MICROBIOME AND GUT-BRAIN AXIS Moderator: Emeran A. Mayer (Los Angeles, USA) Gut brain connection: John Cryan (Cork, Ireland) Serotonin and gut microbiota: Jonathan Lynch (Los Angeles, USA)

05:30 - 07:00 pm Networking Reception

S U N D A Y , M A R C H 8

08:15 - 08:30 am DAY 2 KICKOFF Gail Hecht (Chicago, USA)

PLENARY SESSION 3Microbiome-Druginteractions

Session Moderator: Francisco Guarner (Barcelona, Spain)

08:20 - 08:50 am HUMAN MICROBIOME, DRUG METABOLISM BY GUT BACTERIA AND THEIR GENES — Emily Balskus (Cambridge, USA) 08:50 - 09:20 am THE INFLUENCE OF PROTON PUMP INHIBITORS AND OTHER COMMONLY USED DRUGS ON THE GUT MICROBIOME Rinse K. Weersma (Groningen, The Netherlands) 09:20 - 09:50 am IMPACT OF NON-ANTIBIOTIC DRUGS ON THE GUT MICROBIOTA Athanasios Typas (Heidelberg, Germany)

09:50 - 10:20 am MICROBIOME AND IMMUNE CHECKPOINT INHIBITOR EFFICACY Lisa Derosa (Paris, France)

10:20 - 10:50 am Morning Break

PLENARY SESSION 4Movingmicrobiometotheclinic

Session Moderator: Robert F. Schwabe (New York, USA)

10:50 - 11:50 am PROFILING OF HUMAN-MICROBE SYMBIOSIS; HOW FAR ARE WE FROM CLINICAL APPLICATIONS? Joël Doré (Paris, France) 11:50 - 12:20 pm GUT MICROBIOME AND COLORECTAL CANCER Michael Scharl (Zurich, Switzerland) 12:20 - 12:50 pm DESIGNING DIAGNOSTICS AND THERAPEUTICS FOR THE GUT MICROBIOME David Riglar (London, United Kingdom) 12:50 - 01:00 pm CLOSING REMARKS Gail Hecht (Chicago, USA)

01:00 pm Lunch for all attendees

Giovanni Barbara (Italy)Joël Doré (France)Francisco Guarner (Spain)Dirk Haller (Germany)Harry Sokol (France)Hania Szajewska (Poland)Michael Trauner (Austria)

ESNM / AGA JOINT SCIENTIFIC COMMITTEE

THEFACULTY2020

Gail Hecht (USA) Purna Kashyap (USA) Colleen R. Kelly (USA) Emeran A. Mayer (USA) D. Brent Polk (USA) R. Balfour Sartor (USA) Robert F. Schwabe (USA) Gary D. Wu (USA)

Jessica Allegretti (USA) Fernando Azpiroz (Spain) Emily Balskus (USA) Ran Blekhman (USA) Alberto Caminero (Canada) John Cryan (Ireland) Emily Davenport (USA) Lisa Derosa (France) Gérard Eberl (France) Colin Hill (Ireland) Hana Kahleova (USA) Jonathan Lynch (USA) Kathy McCoy (Canada) Max Nieuwdorp (The Netherlands) Paul W. O’Toole (Ireland) David Riglar (United Kingdom) Michael Scharl (Switzerland) Eran Segal (Israel) Athanasios Typas (Germany) Rinse K. Weersma (The Netherlands) Kevin Whelan (United Kingdom) Moran Yassour (Israel)

GMFH 2020 SPEAKERS AND CHAIRS

ALLEGRETTI JessicaDr.JessicaAllegrettiisanattendinggastroenterologistattheBrighamandWomen’sHospital Crohn’s andColitis Center,where she serves as the center’sDirector ofClinical Trials as well as the hospital’s Fecal Transplant Program Director. Dr. Allegretti’s research focuseson the intestinalmicrobiomeand the consequencesof its derangement, with the goal of understanding the role dysbiosis plays inmicrobialassociateddiseases,specificallyclostridiumdifficile infections(CDI)andinflammatoryboweldisease (IBD).Additionally shehas leadseveral clinical trialsinvestigatingtheroleofFMTinotherchronicdiseasesincludingobesityandprimarysclerosischolangitis.

AZPIROZ FernandoProfessor of Medicine, Autonomous University of Barcelona Consultant, Department of Digestive Diseases, University Hospital General Vall d’Hebron Barcelona, Spain

Fernando Azpiroz is currently Professor ofMedicine and Consultant in DigestiveDiseases at the University Hospital Vall d’Hebron, Autonomous University ofBarcelona,Spain.HegraduatedfrommedicalschoolattheUniversityofValladolid,Spain, in 1977, and trainedat the SanCarlosUniversityHospital,Madrid, andattheMayo Clinic, RochesterMinnesota,where he received the Edward C. KendallAwardforMeritoriousResearch.In1986hejoinedtheValld’HebronDepartmentofDigestiveDiseaseswhereheservedasChiefoftheDepartmentfrom2009to2019.Dr Azpiroz clinical practice develops in a large referral unit, and specifically

Jessica Allegretti (USA) Fernando Azpiroz (Spain) Emily Balskus (USA) Ran Blekhman (USA) Alberto Caminero (Canada) John Cryan (Ireland) Emily Davenport (USA) Lisa Derosa (France) Gérard Eberl (France) Colin Hill (Ireland) Hana Kahleova (USA) Jonathan Lynch (USA) Kathy McCoy (Canada) Max Nieuwdorp (The Netherlands) Paul W. O’Toole (Ireland) David Riglar (United Kingdom) Michael Scharl (Switzerland) Eran Segal (Israel) Athanasios Typas (Germany) Rinse K. Weersma (The Netherlands) Kevin Whelan (United Kingdom) Moran Yassour (Israel)

GMFH 2020 SPEAKERS AND CHAIRS focuseson functionalgutdisorders.His researchprogram investigates theoriginofgastrointestinalsensations.DrAzpirozhasbeendistinguishedwiththeMastersAward in Gastroenterology for Clinical Research in Digestive Diseases, ResearchAward of the International Group for the Study of Gastrointestinal Motility,ResearchScientistAwardoftheFunctionalBrainGutResearchGroup,andSeniorInvestigator-ClinicalScienceAwardoftheInternationalFoundationforFunctionalGastrointestinalDisorder.AtpresentDrAzpirozservesasChairmanoftheMicrobiota&HealthSection,EuropeanSocietyofNeurogastroenterologyandMotility.

BALSKUS EmilyEmily is originally from Cincinnati, Ohio, where she first became interested inchemistryasahighschoolstudent.ShegraduatedfromWilliamsCollege in2002as valedictorian with highest honors in chemistry. After spending a year at theUniversityofCambridgeasaChurchillScholar in the labofProf.StevenLey,shepursued graduate studies in theDepartment of Chemistry andChemical Biology(CCB)atHarvardUniversity,receivingherPhDin2008.HergraduateworkwithProf.EricJacobsenfocusedonthedevelopmentofasymmetriccatalytictransformationsand their application in the total synthesis of complex molecules. From 2008–2011shewasanNIHpostdoctoral fellowatHarvardMedicalSchool in the labofProf. Christopher T. Walsh. Her research in the Walsh lab involved elucidatingand characterizing biosynthetic pathways for the production of small moleculesunscreens by photosynthetic bacteria. She also received training in microbialecology and environmentalmicrobiology as amember of theMicrobialDiversitySummerCourseat theMarineBiologyLabatWoodsHoleduring thesummerof2009.

Emily joined the CCB faculty in 2011 and is currently a Professor of ChemistryandChemicalBiology. She isalsoanAssociateMemberof theBroad InstituteofHarvardandMIT,aFacultyAssociateoftheMicrobialSciencesInitiativeatHarvard,amember of the Harvard Digestive Diseases Center, and amember of theMITCenterforMicrobiomeInformaticsandTherapeutics.Herindependentresearchhasbeenrecognizedwithmultipleawards,includingthe2011SmithFamilyAwardforExcellenceinBiomedicalResearch,the2012NIHDirector’sNewInnovatorAward,andthe2013PackardFellowshipforScienceandEngineering.ShewasselectedasoneofMITTechnologyReview’s35 InnovatorsUnder35 in2014and in2016wasnamedanHHMI-GatesFacultyScholar.

BLEKHMAN RanRanBlekhmanisaMcKnightLand-GrandProfessorattheUniversityofMinnesota.BeforejoiningtheUniversityofMinnesotain2013,Dr.BlekhmanwasaPostdoctoralAssociateworkingwithAndrewG.ClarkatCornellUniversity.HeholdsaPh.D. inHumanGeneticsfromTheUniversityofChicago,whereheworkedwithYoavGilad.TheBlekhmanLabstudieshumangenomicfactorsthatcontroland interactwith

the microbiome. We utilize high-throughput genomics technologies and employcomputational, statistical, machine learning, and population genetic analyticalapproaches, with the goal of understanding how the host genome controls ourmicrobial communities, how themicrobiome regulateshost genes, andhow thishost-microbecrosstalkaffectshumandisease.

CAMINERO AlbertoHisresearchhasbeenfocusedontheroleofbacterialmetabolismofdietaryproteinsinthecontextofintestinaldiseases.Glutenisaclinicallyrelevantgroupofproteinsforhumanhealthanddisease.Ononehand,itconstitutesoneofthemostabundantproteinsourcesinhumandiet,andontheother,aproportionofindividualswithgenetic predisposition who ingest gluten will develop a serious condition calledceliacdisease.DuringhisPhDattheUniversityofLeon(Spain),hehascharacterizedtheduodenalmicrobiota,thesectionoftheintestineaffectedinceliacdisease,andhasshownthatceliacpatientshaveadifferentmicrobiotathanhealthyvolunteers.Healsodeterminedthat thehumangastrointestinal tractharboursbacteria thatmetabolize gluten. This was a key finding, as gluten immunogenicity resides onthe fact that it isnotmetabolizedbyhumandigestiveenzymes.AsamemberofElena Verdu lab during his Postdoctoral fellow atMcMaster University (Canada),hedemonstratedthatintestinalmicrobiotainteractswithdietaryantigensinvivo,suchasglutenandotherimmunogenicwheatproteins,andmodifyitsantigenicitydifferentially,withhigh implicationsongluten-relateddisorders.Healso showedthatmicrobesinthesmallintestinecouldactivateaninnateimmunityinthehostwith implications in food sensitivities. He is currently an Assistant Professor atMcMasterstudyingdiet-microbe interactionsof relevance in Inflammatoryboweldisease.

CRYAN JohnProf. JohnF.Cryantrained inGalway, Ireland,Melbourne,Australia,UniversityofPennsylvania,andTheScrippsResearchInstitute,LaJollabeforespendingfouryearsasaLabHeadinNovartisinBaselSwitzerland.HemovedtoUniversityCollegeCork(UCC)in2005.HerosetheranksandhasbeenProfessor&Chair,Dept.ofAnatomy&Neurosciencesince2011. He isco-authorof thebestselling “ThePsychobioticRevolution: Mood, Food, and the New Science of the Gut-Brain Connection”. HehasreceivednumerousawardsincludingUCCResearcheroftheYearin2012;UCCResearch Communicator of the Year 2017, the University of Utrecht Award forExcellenceinPharmaceuticalResearchin2013.HealsoreceivedaResearchMentorAward from the American Gastroenterology Association and the Tom ConnorDistinguishedScientistAwardfromNeuroscience Ireland in2017.HewaselectedaMemberoftheRoyalIrishAcademyin2017andwasaTEDMEDspeakerin2014.HewasawardedanHonoraryDoctoratefromtheUniversityofAntwerp,Belgiumin2018.He is immediatePast-PresidentoftheEuropeanBehaviouralPharmacologySociety.

DAVENPORT EmilyEmilyR.DavenportisanAssistantProfessorintheDepartmentofBiologyatPennStateUniversitywhoisinterestedinunderstandingtherelationshipbetweenhumansand our microbiomes. Having long been interested in microbes, Dr. DavenportearnedaBachelorof Sciencedegreewith comprehensivehonors inBacteriologyfrom the University of Wisconsin-Madison in 2007. She became familiar withgenomic techniqueswhileworkingat themicroarraycompanyRocheNimbleGenbetween 2007 and 2009. She merged her interests in bacterial and eukaryoticgenomicsduringherPhDinHumanGenetics,whichsheearnedfromtheUniversityofChicago in2014.Shecontinuedtoexploretherolebetweenhostgenetics, themicrobiome,andphenotypeduringapostdocatCornellUniversitybetween2014and2019,which includedayearasavisitingpostdocattheMaxPlanck Institutefor Developmental Biology between 2018 - 2019. Since fall 2019, she has lead alab at Penn State interested in understanding how human gutmicrobiomes aredeterminedandwhatroletheyhaveonhumanhealthandevolution.

DEROSA Lisa DrL.Derosa,MD(cancerimmunotherapyoncologist),PhD(tumorimmunologyandoncomicrobiome),FacultyParisSud,graduatedinMedicalOncologyfromtheSchoolofMedicineoftheUniversityofPisa(Italy).ShestartedherscientificcareerintheLaurenceZitvogellaboratoryatGustaveRoussyasPhDStudentandsheiscurrentlyleading the kidney cancer and lung cancer clinical and translational research in-betweenDrAlbiges’sdepartmentandDrZitvogel’laboratory.Shehasbeenactivelycontributingtothefieldofkidneyandlungcancer, immunology, immunotherapyandmicrobiota, and she brought together basic and translational research. Herexpertiseismainlyhumanandmurinemicrobiota.Thecreativeoutputistheuseoftumor-bearingavatarmicewithfecalmicrobialtransplantationfromcancerpatientsaspredictiveofresistancetocancertherapy.Shehavealsoledcollaborativeeffortswith numerous research groups including those focused on oncomicrobiome,immunology,genitourinarycancers,andraretumorsthroughouthercareer.SheistakingpartinTorinoLumiereandOncobiomenetworksthatexplorethepossibilityto stimulate anticancer immunosurveillance bymanipulating themicrobiome inlung,melanoma,breastandcoloncancerpatients.She istherecipientofseveralawardsandgrants(includingthreeASCOMeritAwardsin2017and2018andtwoESMOMeritAwardsin2014and2018).

DORÉ JoëlJoël isResearchDirectorat INRAMicalis Institute“FoodandGutMicrobiologyforHumanHealth”(www.micalis.fr)andScientificDirectorofMetaGenoPolis(www.mgps.eu),apre-industrialdemonstratorinquantitativeandfunctionalmetagenomicsofthenational“FuturesInvestment”program.Gutmicrobialecologistbytraining,Joëlpioneeredintestinalmetagenomicstowardsfood-microbe-hostinteractionsaswellasdiagnosticapplications.With>30yearsofacademicresearchand>220publications

(HIndex69),Joëlaimstoprovideabetterunderstandingofman-microbessymbiosistowardspersonalizedpreventivenutritionandprecisionmedicine.JoëlislaureateoftheERC-AdvancedHomo.symbiosus;co-founderandscientificadvisorofwww.maat-pharma.com,astartupcompanydedicatedtoprovidesafeandstandardizedmicrobiotherapysolutionsforthereconstructionofhost-microbessymbiosisinthecontext of programmed clinical interventions inducing dysbiosis.Member of theBoD of GMFH, he supports the www.gutmicrobiotaforhealth.com scientific web-platform.

EBERL Gérard Gérard has graduated, completed his PhD and postdocs as an immunologist,investigatingantigensrecognizedbyTcells,thebiologyofso-calledinnateTcells,and the role of lymphoid tissue inducer cells. This latter type of cells became afoundingmember of now the bigger family of innate lymphoid cells (ILCs), andthecoreof theresearchofhis lab for the last14years.Fromhisfirstdayat theInstitut Pasteur in Paris, he has extensively collaboratedwithmicrobiologists toinvestigatethecross-talkbetweenthesymbioticmicrobiota,ILCsandlymphocytes,across-talk that isnecessary tomaintainhomeostasisof thehostanddevelopabalancedimmunesystem.Deregulationofthiscross-talk,histeamhasshown,leadstoinflammatorypathology.Theynowincludethenervoussysteminthisdialogueasapowerfulsensoroftheenvironmentandregulatorofimmuneresponses.Heisparticularlydedicatedtodemonstratethatmicrobesareanimportantelementofourphysiology.Furthermore,hebelievesthattheimmunesystemhastobeanalyzedusingaholisticapproach, inwhichtheothersystemsoftheorganismalsoplayaroleindefense,andinwhichtheimmunesystemisnotonlydesignedfordefense.Withtheseconceptsasworkinghypotheses,hisaimistodevelopnewapproachestopreventthedevelopmentofinflammatorypathologies.

GUARNER FranciscoDr.FranciscoGuarnergraduatedinMedicineattheUniversityofBarcelonain1973,trainedGastroenterologyandHepatologyatHospitalClinic (Barcelona);obtainedPhDdegreeatUniversityofNavarra(Spain).HewasResearchFellowatRoyalFreeHospital(London,UK),King’sCollegeHospital(London,UK),andWellcomeResearchLaboratories(Beckenham,UK).HeisConsultantofGastroenterologyattheDigestiveSystemResearchUnit,UniversityHospitalValld’Hebron(Barcelona,Spain).ChairoftheSteeringCommitteeoftheInternationalHumanMicrobiomeConsortium(www.human-microbiome.org), member of the Scientific Committee of Gut MicrobiotaforHealthSectionoftheEuropeanSocietyofNeurogastroenterologyandMotility(www.gutmicrobiotaforhealth.com),andpastmemberoftheBoardofDirectorsontheInternationalScientificAssociationforProbioticsandPrebiotics(isappscience.org).Co-authorof319publicationsonoriginalresearchorreviews(WebofScience),holdsanh-indexof62.

HALLER DirkTechnical University of Munich, Chair of Nutrition and ImmunologyDirector ZIEL Institute for Food & Healthwww.nutrition-immunology.de

The main areas of research of Prof. Haller are dedicated to the understandingof microbe-host interactions in the digestive tract. Nutrition and the intestinalmicrobiome play a pivotal role in the development of complex pathologies andakeyquestionofProf.Hallerandhis team ishowthese intestinalmilieu factorsmodulate inflammatory and tumorigenic responses. The intestinal epitheliumprovides a dynamic interface to sense themetabolic andmicrobial environmentin the gut and the unfolded protein response is a prime target of his researchactivities.Inthepastyears,Prof.Hallerandhisteamgeneratedacomprehensiveand conclusive understanding how complex microbial communities and specificmechanismsofmicrobe-host interactionsaffectchronic inflammationandtumordevelopmentusingnovelgerm-freeandgnotobioticmodels.Inaddition,andmostimportantlytoimplementtranslationalresearch,humaninterventiontrialssupportthemechanisticstudiesinmodelsandaimatdefiningthefunctionalrelevanceofmicrobiomesignaturesinhealthypopulations(prospectivecohortKORAandinfants)and patients (IBD and colon cancer). In the past years, Prof. Haller establishedcomprehensiveresearchprogramatthenational(DFG)PriorityProgramSPP1656,andlocallevel(DFGCollaborativeResearchCenterCRC1371;ZIELInstituteforFood&Health) tounravel the roleof thegutmicrobiome inhealthanddisease. Prof.Haller published 170 publications in international journals (h-index 47, Scopus;ranked1%mostcitedscientists).

HECHT GailDr. Hecht is Professor ofMedicine andMicrobiology/Immunology and served asChief, Gastroenterology and Nutrition at Loyola University Medical Center untilJuly 2019. She earnedherMD fromLoyolaUniversity Stritch School ofMedicine,completedInternalMedicineResidencyattheUniversityofMinnesota,Minneapolis,andherFellowshipinGastroenterologyatBrighamandWomen’sHospital,HarvardMedical School. Her initial faculty appointment was at the University of IllinoisChicagowheresherosethroughtherankstoProfessorandwasappointedChiefofDigestiveDiseasesandNutrition.SherelocatedtoLoyolainJanuary2013.SheservesasEditor-in-ChiefofthejournalGutMicrobespublishedbyTaylor&FrancisGroup.Dr. Hecht has been very active in the American Gastroenterological AssociationfunctioningasChairoftheIntestinalDisordersSectionoftheAGACouncil,asBasicResearchCouncilortotheGoverningBoardandultimatelyservingasPresidentfrom2009-2010,onlythesecondwomantoserveinthatcapacity.

HILL ColinColinHillhasaPh.DinmolecularmicrobiologyandisProfessorofMicrobialFoodSafety in theSchoolofMicrobiologyofUniversityCollegeCork, Ireland.Hismaininterests are in infectious disease, particularly in defining the mechanisms ofvirulence of foodborne pathogens and in developing strategies to prevent andlimit the consequencesofmicrobial infections in the gastrointestinal tract.He isparticularly interested intheantimicrobialeffectsofprobiotics,bacteriocins,andbacteriophage.HeisalsoaPrincipalInvestigatorinAPCMicrobiomeIrelandinCork,a largeresearchcentredevoted to thestudyof theroleof thegutmicrobiota inhealthanddisease.In2005Prof.HillwasawardedaD.ScbytheNationalUniversityofIrelandinrecognitionofhiscontributionstoresearch.In2009hewaselectedtotheRoyalIrishAcademyandin2010hereceivedtheMetchnikoffPrizeinMicrobiologyandwaselectedtotheAmericanAcademyofMicrobiology.Hehaspublishedmorethan540papersandholds20patents.HewaspresidentofISAPPfrom2012-2015.

KAHLEOVA HanaDr. Kahleova is director of clinical research for the Physicians Committee forResponsibleMedicine.Shehasconductedseveralclinicaltrials,usingaplant-baseddiet in the treatment of obesity, diabetes, and metabolic disease. Her researchshowedthataplant-baseddietleadstoagreaterweightlossandimprovementinmetabolism,andaddressesmultiplemechanismsbehinddiabetes.

Herresearchprovedthateatingalargebreakfastandlunchismorebeneficialthaneatingsixsmallermealsadayforpatientswithtype2diabetes.Herresearchonmealfrequencyandtimingshowedthateatinglessfrequently,nosnacking,consumingbreakfast,andeatingthelargestmealinthemorningmaybeeffectivemethodsforpreventinglong-termweightgain.

As a member of the American Diabetes Association and as a board member of the DiabetesandNutritionStudyGroupoftheEuropeanAssociationfortheStudyofDiabetes,Dr.Kahleovaisdirectlyinvolvedintheprocessofupdatingthenutritionalrecommendationsforpatientswithdiabetes.

KASHYAP PurnaDr.PurnaKashyapisanAssociateProfessorofMedicine,PhysiologyandBiomedicalEngineeringandtheCo-ProgramDirectoroftheMicrobiomeprogramintheCenterforIndividualizedMedicineatMayoClinic,Rochester,MN.HeisafellowoftheAmericanGastroenterology Association and member of their Center for Gut MicrobiomeEducationandResearch,andservesonthecouncilofAmericanNeurogastroenterologyandMotilitySociety.HeistheassociateeditorofGutMicrobesjournalandservesontheeditorialboardofNeurogastroenterologyandMotilityandFASEBjournal.Dr.Kashyap’sGutMicrobiomeLaboratoryisinterestedinunderstandingthecomplexinteractionsbetweendiet,gutmicrobes,andgastrointestinalfunction.Deleterious

alterationsingutmicrobiotahavebeenassociatedwithanumberofdiseasestatessuch as Clostridium difficilecolitis,functionalboweldisorderssuchasirritablebowelsyndrome, andmetabolic diseases such as obesity.However, the functional roleof gutmicrobes in thedevelopmentof thesediseases remains largelyunknown.Tobetterunderstandtheroleofgutmicrobes,Dr.Kashyap’slaboratoryintegratesdata generated frommulti-omicplatformswith in vivoand in vitrophysiologicalmeasurementsfromhumanresearchparticipantsandgnotobioticmousemodelsto elucidate interactions amongmicrobiota-derived bioactivemolecules and thekeyregulatorsofgastrointestinal function.Bycombiningexperimental strategieswithbioinformaticsanalysis,Dr.Kashyap’sresearchteamhopestodevelopnovelmicrobiota-targetedtherapiestotreatpatientswithdisordersresultingfromalteredmicrobiota function.

KELLY Colleen R.MD, FACGAssociate Professor of MedicineWarren Alpert Medical School of Brown UniversityThefocusofDr.Kelly’sresearchandclinicalpracticeisClostridium difficile infection (CDI)andfecalmicrobiotatransplantation(FMT).Shewastheprincipalinvestigator(PI)forafirstplacebo-controlledtrialofFMTfortreatmentofrecurrentCDIandoneofthefirstinvestigatorstosponsorofaninvestigationalnewdrug(IND)applicationforFMTwith theFoodandDrugAdministration.ShehassinceservedonseveralworkinggroupsfocusingonregulatoryissuesrelatedtoFMT.Dr.Kellyiscurrentlysite PI for an industry funded trial of livemicrobiota for treatment of recurrentCDI aswell as investigator-initiated clinical trials assessing conventional FMT forCDItreatment.Dr.Kellyisinterestedinthelong-termeffectsaroundmanipulationof gutmicrobiota and serves as one of the PIs for anNIH-funded FMTNationalRegistry which will answer important questions around the safety of FMT. Shehas collaborated on several studies investigating the impact of FMT on patientswith InflammatoryBowelDisease,Nonalcoholic Fatty LiverDiseaseandAlopeciaAreata. In addition to coauthoring current FMT guidelines and participating indrafting the European Consensus Conference on Fecal Microbiota Transplant inClinicalPractice, she servesas theprimaryauthor for the forthcomingAmericanCollegeofGastroenterology(ACG)2019C. difficile treatmentguidelines.Dr.KellyisaFellowintheACGandisaFellowandpastmemberofthescientificadvisoryboardforGutMicrobiomeResearchandEducationof theAmericanGastroenterologicalAssociation.

LYNCH JonathanJonathanwasaNationalScienceFoundationGraduateResearchFellowandreceivedhisPhD inMicrobiologyand Immunology from the StanfordUniversity School ofMedicine.HeperformedhisthesisworkinthelabofDr.JustinSonnenburg,wherehestudiedhowanabundantclassofsignalingproteins,thehybridtwo-component

systems,governednutrientsensinginthegutmicrobiota.HewasthenaNationalInstitutesofHealthRuthL.KirschsteinpostdoctoralfellowinthelabofDr.NedRubyattheUniversityofHawaii,whereheleveragedthemodelsquid-Vibriosymbiosisto study howmutualistic bacteria sense and respond to their host environmentthrough membrane modifications and regulated motility. He recently started apositionasanassistantprojectscienceinthelabofDr.ElaineHsiaoattheUniversityofCalifornia-LosAngeles,whereheisstudyingtheinteractionsbetweengutbacteriaandtheregulationofserotonininthemammalianintestine.

MAYER Emeran A.Emeran A Mayer is Professor in the Departments of Medicine, Physiology andPsychiatry at theDavidGeffen School ofMedicine atUCLA. He is the ExecutiveDirectoroftheGOppenheimerCenterforNeurobiologyofStress&Resilienceandtheco-directorof theCURE:DigestiveDiseasesResearchCenteratUCLA.Asoneofthepioneersandleadingresearchersintheroleofmind-brain-gutinteractionsinhealth and chronicdisease, hehasmademajor scientific contributions to theareaofbasicandtranslationalentericneurobiologywithwide-rangingapplicationsin clinical GI diseases and disorders. He has publishedmore than 300 scientificpapers(h-factor111),andcoedited3books,andhisbestsellingbookTheMindGutConnectionhasbeenpublishedbyHarper&Collinsin2016andhasbeentranslatedinto12languages.

MC COY KathyDr.KathyMcCoyisaProfessorintheDepartmentofPhysiologyandPharmacology,Cumming school of Medicine, and the Scientific Director of the InternationalMicrobiome Center at the University of Calgary, Canada. Her research groupuses germ-free and gnotobioticmodels to investigate the cellular andmolecularmechanismsbywhichthemicrobiomeregulateshostimmunityandphysiology.Sheisparticularlyinterestedinthedynamicinterplaybetweenthegutmicrobiotaandthe innateandadaptive immunesystems.Herresearchaimstounderstandhowexposuretointestinalmicrobes,particularlyduringearlylife,educatesandregulatesthe mucosal, systemic and neuronal immune systems and how this can affectsusceptibilitytodiseases,suchasallergy,autoimmunity,andneurodevelopmentaldisorders. Her lab also investigates how the microbiome regulates the immunesystem throughout life with the aim to identifymicrobial therapies that can beemployedtoenhancecurrenttherapeuticapproaches,suchasincancer.

O’TOOLE Paul W.School of Microbiology and APC Microbiome Ireland, University College Cork, Ireland.

Paul O’Toole is Professor of Microbial Genomics and head of the School ofMicrobiologyatUniversityCollegeCork,Ireland.HeisaPrincipalInvestigatorintheAPCMicrobiomeInstitute(apc.ucc.ie).Hismainresearchthemeisthemetagenomicsof gastrointestinalbacteria inhumans,withemphasison lactobacillus genomics,gutmicrobiota in ageing, colorectal cancer and in IBS. He has co-ordinated andparticipatedinseveralmajorprojectsthatexaminethecompositionandfunctionof thegutmicrobiota, its reactiontohabitualdiet,and its relationship tohealth,functionalgastrointestinaldisorders,andageing.Theultimateaimistounderstandandmanipulatehost-microbiome interactions, especially in the context ofmulti-factorial disease. He co-ordinated the ELDERMET project (eldermet.ucc.ie) thatestablisheddiet-microbiotahealthinteractionsin500elderlypersons,ELDERFOODthatinvestigatednoveldairyingredientsforhealthyaging,arecentAPCprebioticinterventionintheelderly,andthemicrobiomeanalysisoftheEUprojectNuAge,thatinvestigatedtheeffectofaMediterraneandietonthemicrobiomeandhealthof600oldersubjectsacrossEurope.HehasparticipatedinmultipleotherEUprojects.Research inhis lab issupportedbyScienceFoundation Ireland,Dept.AgricultureFisheriesandMarine, theHealthResearchBoard, variousAPC industrypartners,and the European Union.

POLK D. BrentProfessor of PediatricsPediatric Gastroenterology, Hepatology & NutritionProfessor of Biochemistry & Molecular MedicineVice Dean for Child Health - USCUniversity of Southern California and Children’s Hospital Los Angeles BrentPolk isProfessorofPediatricsandBiochemistry&MolecularMedicineandvicedeanforchildhealthattheKeckSchoolofMedicineofUniversityofSouthernCalifornia(USC).HeistheformerchairoftheDepartmentofPediatricsforUSCandpastchiefofpediatrics,physician-in-chiefandvicepresident foracademicaffairsand director of the Saban Research Institute at Children’s Hospital Los Angeles(CHLA).Adistinguishedinvestigator,clinicianandeducator,Dr.Polkhasmorethan25 years of experience as a pediatric physician-scientist focused on the care ofpatientswithinflammatoryboweldisease(IBD),withthegoalofaskingquestionsthrough laboratory investigations – informed by patient care challenges – thatmaybe translatedback to identify risksofdiseaseand targets forpreventionortreatment.Hislaboratoryisfocusedontheregulationofgrowthanddevelopmentoftheintestinalcellasitrelatestodevelopmentanddisease,withaparticularfocusonsignaltransductionmechanismsinIBD.HecurrentlyservesastheChairoftheNational Scientific Advisory Committee of the Crohn’s & Colitis Foundation andChairoftheGastrointestinalMucosalPathobiologyStudy(GMPB)StudySectionoftheNIH.

RIGLAR DavidDavidRiglarrecentlystartedalaboratoryintheDepartmentofInfectiousDiseaseatImperialCollegeLondon,fundedbyaprestigiousSirHenryDaleFellowshipfromtheWellcomeTrustandRoyalSociety.Hislab’sresearchaimstodevelopengineeredbacteriaastoolstoprobeandmanipulatethemammaliangutmicrobiota.Usingthesetools togetherwith imagingandsequencingbasedapproaches,he isparticularlyinterested to understand how the bacteria that comprise the mammalian gutmicrobiotavarytheirfunctionspatiallywithinthegutduringinflammatorydiseaseconditions.DavidundertookhispostdocatHarvardMedicalSchoolasanNHMRC/RGMenziesandHumanFrontierScienceProgramfellowwithPamSilverandhisPhDasaPrattFoundationScholarattheWalterandElizaHallInstitute,AustraliawithJakeBaumandAlanCowman.

SCHARL MichaelDrMichaelScharlobtainedhismedicaldegreefromtheUniversityofRegensburgin Germany and followed with two years of post-doctoral research at UC SanDiego,DivisionofGastroenterology.DrScharlisendowedPeterHansHofschneiderProfessor for Molecular Medicine, Head of Research, Senior Physician, FacultyMember and Lecturer in Gastroenterology at the University Hospital Zurich andUniversityofZurich.Hisresearchfocusesoninnateandadaptiveimmuneresponsesinthepathogenesisofintestinalinflammationandintestinalcarcinomaswiththeaimofachievingabetterunderstandingofthecomplexinterplaybetweengeneticpredispositions, intestinal microbiota and aberrant immune responses in thedevelopmentofdiseases.

SEGAL EranEran Segal is a Professor at the Department of Computer Science and AppliedMathematics at the Weizmann Institute of Science, heading a lab with a multi-disciplinary team of computational biologists and experimental scientists in thearea of Computational and Systemsbiology.His grouphas extensive experienceinmachine learning, computationalbiology,probabilisticmodels,andanalysisofheterogeneoushigh-throughputgenomicdata.HisresearchfocusesonMicrobiome,Nutrition,Genetics,and theireffectonhealthanddisease.Hisaim is todeveloppersonalizednutritionandpersonalizedmedicine.Prof.Segalpublishedover140publications,andreceivedseveralawardsandhonorsforhiswork, including theOvertonprize, awardedannuallyby the InternationalSocietyforBioinformatics(ICSB)toonescientistforoutstandingaccomplishmentsincomputationalbiology,andtheMichaelBrunoaward.HewasrecentlyelectedasanEMBOmemberandasamemberoftheyoungIsraeliacademyofscience.Before joining theWeizmann Institute,Prof. Segalheldan independent researchpositionatRockefellerUniversity,NewYork.

Prof. SegalwasawardedaB.Sc. inComputerSciencesummacum laude in1998,fromTel-AvivUniversity, and a Ph.D. in Computer Science andGenetics in 2004,from Stanford University. Labwebsite:http://genie.weizmann.ac.il

SOKOL HarryHarrySokol,isProfessorintheGastroenterologydepartmentoftheSaintAntoineHospital(APHP,Paris,France),theco-directoroftheMicrobiota,Gut&Inflammationteam (INSERM CRSA UMRS 938, Sorbonne Université, Paris) and group leader inMicalis institute (INRA). Harry Sokol is an internationally recognized expert inInflammatoryBowelDisease(IBD)andingutmicrobiotafields.Hepublishedover180papersonthesetopicsinmajorjournals(includingGut,Gastroenterology,CellMetabolism, Cell Host &Microbe, Nature communication, NatureMedicine). HisworkontheroleofthegutmicrobiotainIBDpathogenesisledtolandmarkpapersdescribingtheIBD-associateddysbiosis(imbalanceingutmicrobiotacomposition)and the role of the pivotal commensal bacteria Faecalibacterium prausnitzii ingut homeostasis and in IBD. Currently, his work focuses on deciphering the gutmicrobiota-host interactions inhealthanddiseases (particularly IBD), inorder tobetterunderstand their role inpathogenesisanddevelop innovative treatments.Harry Sokol is exploring particularly the role of the microbiota in tryptophanmetabolismforwhichheisrecipientofanERCgrant.Besidebasicscience,heisalsoinvolvedintranslationalresearch.HeisthecurrentpresidentoftheFrenchgroupoffecalmicrobiotatransplantation,hecoordinatedapilotrandomizedcontroltrialevaluatingfecalmicrobiotatransplantationinCrohn’sdiseaseandheiscurrentlycoordinating a phase III nationwide randomized control trial evaluating fecalmicrobiotatransplantationinulcerativecolitis.Homepage: https://sites.google.com/site/harrysokol/Twitter: @h_sokol

TYPAS AthanasiosAthanasios(Nassos)Typasisatrainedbiochemist,geneticist,andsystemsbiologist.HeleadsagroupattheGenomeBiologyUnitatEMBL,Heidelberg,Germanysince2011. His group combines systems microbiology with molecular mechanism tostudy bacterial cellular networks, and how bacteria interact with each other,theenvironmentand thehost.Akey focalareaof thegroup isondrug-microbeinteractions:identifyingnewtherapeuticstrategies,understandingandpredictingthedrugmodeofactionandcellularresistancepotential,anddissectingtheinterplayofmedicationwiththegutmicrobiome.Nassoshasreceivedanumberofawards(NIHK99/R00,SofjaKovalevskajaAward-HumboldtFoundation,ERCconsolidatorgrant)andisamemberoftheEuropeanAcademyofMicrobiology.

WEERSMA Rinse K.Gastroenterologist, Head of the Department, Full Professor, Department ofGastroenterologyandHepatology,UniversityMedicalCenterGroningen,UniversityofGroningen,Netherlands

CURRENTPOSITIONS2016-now:ChairoftheDepartmentofGastroenterologyandHepatologyUniversityMedicalCentreGroningen,Groningen,theNetherlands2015-nowCo-ChairGroningen InstituteonGastro IntestinalGeneticsand Immunology(3GI)2013-nowFullProfessor“Compleximmunemediatedgastrointestinaldiseases”UniversityofGroningenandUniversityMedicalCentreGroningen,PREVIOUSPOSITIONS-2015:VisitingScientistHarvardMedicalSchool,MassachusettsGeneralHospital,BostonUSAandtheBroadInstituteCambridge,USA.

WHELAN KevinKevinWhelanistheProfessorofDieteticsandHeadoftheDepartmentofNutritionalSciencesatKing’sCollegeLondon.HeisaPrincipalInvestigatorleadingaresearchprogrammeexploringtheinteractionbetweendiet,thegastrointestinalmicrobiotaandhealthanddisease.Hehasundertakennumerousmulti-centreinvestigationsof the microbiota in patients with inflammatory bowel disease, irritable bowelsyndromeandpatientsreceivingartificialnutrition,andtheuseofdiettomodifythese. He has published over 150 peer-reviewed papers on the topics of fibre,probiotics, prebiotics and FODMAPs. He is the Series Editor of the ‘‘AdvancedNutrition and Dietetics’’ Book Series consisting of four books (Gastroenterology,Diabetes,Obesity,NutritionSupport).In2012hewasawardedtheNutritionSocietyCuthbertsonMedal for clinical nutrition, in 2017 was appointed a Fellow of theBritishDieteticAssociationandin2018deliveredtheDrElsieWiddowsonMemorialLecture.

YASSOUR MoranDr.MoranYassourisaseniorlecturerattheHebrewUniversity,FacultyofMedicine,withjointaffiliationattheschoolofComputerScienceandEngineering.TheYassourlabstudiesthedevelopmentofthehumanmicrobiomeinhealthanddisease,bydevelopingnewcohortstostudytheestablishmentofthenewborngutmicrobiomeandcharacterizethemother-to-childbacterialtransmission.Moran recently finished her postdoctoral training at the Broad Institute of MITandHarvard University, with Ramnik Xavier and Eric Lander, where she studiedthehumangutmicrobiome.DuringherPhDintheFriedman(HebrewU)andRegev(MIT/Broad)labs,shedevelopedtoolstoreconstructthetranscriptomeofpartiallyassembledgenomesandaberrantcancergenomes.MoranreceivedherB.Sc.,M.Sc.,andPh.D.incomputerscienceandcomputationalbiologyfromtheHebrewUniversityofJerusalem.

The Gut Microbiota For Health World Summit is a scientific event sponsored bythe European Society for Neurogastroenterology & Motility (ESNM)

and the American Gastroenterological Association (AGA),with the endorsement of the American Neurogastroenterology and Motility Society

(ANMS).

COM

E TO

TH

E W

ORL

D 2

020

OFFICIAL PCO

45 rue de Lourmel • 75015 Paris • FrancePhone: +33 1 83 63 70 21www.cometotheworld.fr

CONGRESS INFORMATION / SPONSORSHIP ENQUIRIESgmfh@cometotheworld.fr

GENERAL COORDINATION & PRODUCTIONFarid Chabéni

Email: fchabeni@cometotheworld.fr - Phone: +33 6 60 56 61 30

LOGISTICAL COORDINATION & REGISTRATION ENQUIRIESLony Castans

Email: lcastans@cometotheworld.fr - Phone: +33 6 24 05 28 22

2020